# Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

> **NCT03370120** · PHASE2 · TERMINATED · sponsor: **UCB Biopharma SRL** · enrollment: 406 (actual)

## Conditions studied

- Drug-Resistant Epilepsy
- Focal-Onset Seizures

## Interventions

- **DRUG:** Padsevonil

## Key facts

- **NCT ID:** NCT03370120
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-27
- **Primary completion:** 2020-12-11
- **Final completion:** 2020-12-11
- **Target enrollment:** 406 (ACTUAL)
- **Why stopped:** Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure
- **Last updated:** 2021-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03370120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03370120, "Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03370120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*